[Teratogenic effects of 9-hydroxy-ellipticine in mouse embryo].
Administered to pregnant Mice of Swiss strain, at stages of 9 to 12 days of gestation and at doses of 15 to 50 mg/kg, 9-hydroxy-ellipticine acts as an acute teratogen; it induces in embryos, cleft palate and limb deformities. Histological examination of embryos from mothers treated by a dose of 30 mg/kg at day 10 or 11 revealed defects in the eyes, spinal cord and a reduction in the number of germinal cells.
D000470:Alkaloids / Q000633:toxicity*; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D004611:Ellipticines / Q000633:toxicity*; D004622:Embryo, Mammalian / Q000187:drug effects*; D005123:Eye / Q000187:drug effects / Q000196:embryology; D005260:Female; D005865:Gestational Age; D008297:Male; D051379:Mice; D011247:Pregnancy; D013116:Spinal Cord / Q000187:drug effects / Q000196:embryology; D013723:Teratogens; D013737:Testis / Q000187:drug effects / Q000196:embryology
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D013723:Teratogens; C008009:9-hydroxyellipticine
Effets tératogènes de l'hydroxy-9-ellipticine chez l'embryon de Souris.